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Abstract: Since the publication of the US Surgeon General Reports in 1996 and 2006 and 
the report of the California Environmental Protection Agency in 1999, many reports have 
appeared on the contribution of air and biomarkers to different facets of the secondhand 
smoke (SHS) issue, which are the targets of this review. These recent studies have allowed 
earlier  epidemiological  surveys  to  be  biologically  validated,  and  their  plausibility 
demonstrated,  quantified  the  levels  of  exposure  to  SHS  before  the  bans  in  various 
environments, showed the deficiencies of mechanical control methods and of partial bans 
and  the  frequently  correct  implementation  of  the  efficient  total  bans.  More  stringent 
regulation  remains  necessary  in  the  public  domain  (workplaces,  hospitality  venues, 
transport sector, etc.) in many countries. Personal voluntary protection efforts against SHS 
are also needed in the private domain (homes, private cars). The effects of SHS on the 
cardiovascular,  respiratory  and  neuropsychic  systems,  on  pregnancy  and  fertility,  on 
cancers and on SHS genotoxicity are confirmed through experimental human studies and 
through  the  relationship  between  markers  and  prevalence  of  disease  or  of  markers  of 
disease risk. 
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1. Introduction 
The main issues of secondhand smoke (SHS) have been extensively addressed in two successive 
reports of the US Surgeon General [1,2] and in the report of the California Environmental Protection 
Agency [3]. 
Early  publications  about  the  health  consequences  of  SHS  (also  referred  to  as  Environmental 
Tobacco Smoke [ETS]) were mainly epidemiological surveys through questionnaires for general or 
specific populations. Their value is limited, as the respondents’ answers may (voluntarily or not) be 
incorrect and the large numbers of factors influencing the prevalence, intensity and duration of SHS 
exposure cannot be correctly estimated in a questionnaire. On the other hand, measurement of air- and 
biomarkers of SHS exposure is more quantitative and can complement and validate the results of the 
questionnaire surveys. 
Recent contributions of air- and biomarkers to different facets of the SHS issue are reviewed in this 
paper. Medline was searched from 2005 with the keywords ―SHS‖ and ―air‖ or ―atmospheric markers‖ 
and ―SHS and biomarkers‖. The full collection of Tobacco Control and Nicotine & Tobacco Research 
was examined from 2005 onward, and some references from bibliographies were also recorded. The 
Cochrane Review 2010 [4] was another source of information. To produce an overview compatible 
with the length of a review article, some publications were summarized and others had to be set aside.  
Experimental studies on cells, germs and animals, transplacental foetus exposure during pregnancy 
and the economic consequences of smoking bans were excluded, as were the health effects of SHS 
estimated from risk models.  
2. Methodological Issues in Markers 
2.1. Atmospheric Markers 
Among the potential atmospheric markers of SHS, carbon monoxide (CO) is usually excluded due 
to  its  poor  specificity,  although  its  non-tobacco-specific  origin  in  closed  environments  is  easily 
detected. In ambient air, its safe limit was fixed at 8.5 ppm in a European Directive [5]. 
Nicotine is a specific, sensitive and valid marker of atmospheric SHS that is absent in tobacco 
smoke-free  environments.  Air  nicotine  can  be  used  to  estimate  respirable  particulate  matter  (PM) 
exposure from SHS in indoor environments if smoking occurs regularly, if the system is in a near 
quasi-steady  state  and  if  the  sampling  time  is  longer  than  the  characteristic  times  for  removal  
processes [6].  
Despite  a  background  concentration  of  respirable  particulate  matter  (PM)  due  to  cooking  and 
infiltration from outdoors, PM is considered as a surrogate marker of SHS, at least at relatively high 
levels [2]. PM < 10 µm enter the respiratory tract, but are primarily produced by mechanical processes 
such as construction activities, road dust resuspension and wind. PM < 2.5 µm (fine particles) originate 
primarily from combustion sources (such as smoking). Their background value has been estimated to 
be 3–5 µ g/m
3 in the US and Western Europe, and the limit of air quality is estimated at 10 µ g/m
3 
annual mean and 25 µ g/m
3 24 h mean. Those limits are those when respectively long versus short term 
health effects are expected to appear. For ultrafine particles (<0.1 µ m), no recommendation can be Int. J. Environ. Res. Public Health 2011, 8                 
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provided, as the existing body of epidemiological evidence on the exposure-response relationship is 
insufficient [7].  
Mathematical models were developed and applied to existing statistics in order to predict respirable 
SHS suspended particles (<3.5 µ m) and nicotine in air inside the home from building smoke density, 
air exchange rate, exposure duration, etc., to convert serum cotinine into urine cotinine, and to estimate 
atmospheric  SHS-PM  and  nicotine  from  cotinine  in  vital  products.  These  models,  called  ―Rosetta 
Stone‖ Equations by Repace, permit broad comparison of clinical and epidemiological studies using 
respectively atmospheric markers and biomarkers for SHS [8]. For each microgram of atmospheric 
nicotine, there is an estimated increase of about 10 µ g in respirable SHS particle concentration [1].  
Fluorescing particulate matter (FPM) and ultraviolet-absorbing particulate matter (UVPM) are also 
sensitive  atmospheric  markers  [1],  although  not  frequently  used.  The  carcinogenic  particulate 
polycyclic aromatic hydrocarbons (PPAH) are also used for measuring air quality [9,10]. Benzene, 
another  carcinogenic  substance  of  tobacco  smoke,  is  sometimes  used  as  an  air  marker  of  SHS  
(UE security limit for ambient air: 5 mcg/m
3 [5]. For volatile organic compounds and semi-volatile 
compounds, sorption on and desorption from indoor surfaces influence exposure.  
2.2. Biomarkers 
The characteristics of an ideal SHS biomarker are the following: specificity for tobacco, appropriate 
half-life, sensitivity and precision, sampling with non-invasive techniques, low cost, association with 
health effects or with an agent having health effects, quantitative relationship to prior exposure to  
SHS [1].  
CO in exhaled air and blood HbCO are both inadequate biomarkers of exposure to SHS due to poor 
specificity  and  a  short  half-life.  Thiocyanate  is  inadequate  due  to  lack  of  sensitivity.  Nicotine  is 
specific, but its variations due to its 1–3 h half-life limit its value as a marker of exposure. When 
measured in hair (where it is incorporated into the growing shaft over time), nicotine seems to be a 
better  marker  of  chronic  exposure.  Hair  nicotine  levels  were  better  able  to  identify  infants  aged  
3–27 months according to smoking in their households (no smoking, smoking only outside the home, 
smoke inside the home) than urine nicotine (p < 0.0001), and were correlated with the number of 
smokers [11]. An evident positive association between hair nicotine concentrations in non-smokers and 
higher numbers of cigarettes smoked per day in a household was demonstrated [12]. Of a total of  
1,746  cases  from  six  US,  Canada  and  France  databases,  the  cut-off  value  of  hair  nicotine 
distinguishing active smokers from passive smokers or subjects unexposed to smoke were 0.8 ng/mg 
for  non-pregnant  and  0.2  ng/mg  for  pregnant  women.  The  cut-off  value  between  exposed  and 
unexposed children was 0.2 ng/mg [13].  
In 2,485 women participating in the Nurse's Health Study in 1982, toenail nicotine levels differed 
significantly  according  to  reported  smoking  status  (median  level  for  non-smokers  without  SHS 
exposure 0.10 ng/mg; with SHS exposure 0.14 ng/mg; and for active smokers 1.77 ng/mg), but with 
considerable overlap in nicotine levels between the reported types of smoking status [14]. Its value is 
thus limited.  
Cotinine, the main metabolite of nicotine, is used most frequently as its half-life (± 16–18 h) [15] 
allows levels to remain fairly constant during the day. The cut-off point of 14 ng/mL plasma cotinine Int. J. Environ. Res. Public Health 2011, 8                 
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currently used overestimates the number of non-smokers, and a new overall cut-off point of 3 ng/mL 
between smokers and non-smokers has been proposed, based on data from 3,078 smokers and 13,078 
non-smokers. This shift is due to the decline in SHS exposure in the US in recent years [16].  
Optimal  end-points  for  saliva  cotinine  concentration  between  smokers  and  non-smokers  vary 
according  to  the  presence  (18  ng/mL)  or  absence  (5  ng/mL)  of  smoking  in  the  home  [15].  
Saliva cotinine concentration closely parallels serum concentration (saliva cotinine concentration =  
serum ×  1.1 to 1.5) [17-20].  
Urine cotinine concentrations are also highly correlated with blood concentrations (r ±  0.8) [20-22]. 
The  ratio  of  urine  to  plasma  cotinine  is  on  average  4  to  5  [23].  Correction  of  urine  cotinine  for 
creatinine concentration improves the correlation between urine and plasma cotinine (R = 0.91–0.95). 
A plasma cotinine concentration of 1 ng/mL corresponds to a daily intake of 100 µ g of nicotine [24].  
Inter-subject variability reduces the accuracy of the relationship between nicotine intake and plasma 
cotinine for individuals in comparison with population studies. Cotinine measures from single urine 
samples  provide  accurate  estimates  of  recent  exposure  (2–3  days)  in  groups  of  children,  but  for 
estimates of the mean cotinine levels of an individual child over 4–15 days, up to nine urinary samples 
may be necessary, and up to 12 urinary samples for exposure over a 4- to 13-month period [25]. 
The  different  cut-off  points  distinguishing  between  cigarette  smokers  and  non-smokers  from 
different racial/ethnic groups (between 1 and 6 ng/mL vs. the overall cut-off point of 3 ng/mL serum 
cotinine [16]) are probably related to racial differences in global levels of exposure in daily life, as 
after  exposure  of  40  non-smokers  for  4  hours  (men  and  women,  African-Americans  and  whites)  
to  aged  diluted  sidestream  smoke  in  an  environmental  chamber  under  uniform  conditions,  the  
increase in biomarker levels (cotinine or (4-methylnitrosaminol)-1-(3-pyridyl)-1-butanol [NNAL] or  
4-aminobiphenyl [4AB] adducts) were similar in all groups [26].  
The cut-off point between smokers and non-smokers exposed to SHS is also influenced by the fact 
that in non-daily smokers, who represent more than 30% of cigarette smokers [27], the short-term 
biomarkers of exposure could decrease to non-smoker levels in the period between smoking episodes.  
A 24 h urine collection of the sum of four or six of the major nicotine metabolites is correlated 
better than cotinine with small doses 100–400 µg (in the range of SHS) of deuterium-labeled nicotine 
administered per os daily for 5 days [28]. 
Nicotine  is  detected  by  colorimetry  and,  as  well  as  cotinine,  by  various  immunologic  and 
chromatographic  methods,  completed  or  not  with  mass  spectrometry.  Immunologic  techniques  are 
adequate for large samples and chromatographic methods for more precise and limited studies. 
Serum cotinine measurements were compared in experienced laboratories using either gas-liquid 
chromatography with nitrogen-phosphorus detection or liquid chromatography with mass spectrometry 
detection  in  concentrations  ranging  from  0.05  ng/mL  to  high  concentrations  of  active  smokers. 
Accurate and precise results were observed without interlaboratory bias [29]. 
The combination of a biomarker and self-reported exposure is considered a better way of estimating 
exposure than serum cotinine levels alone, as time delays between SHS exposure and blood collection 
can  influence  cotinine  values.  In  the  Monica  Study,  the  kappa  coefficient  for  agreement  between  
self-reported  exposure  (in  various  questionnaires)  and  serum  cotinine  levels  is  always  <0.24, 
considered as only a fair agreement between the two methods [30]. The level of agreement differs in 
other studies due to differences in wording of questions, type of population, type of analysis, etc. Int. J. Environ. Res. Public Health 2011, 8                 
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Among  183  pregnant  Polish  women,  for  example,  serum  cotinine  levels  corresponding  to  active 
smoking were detected in 17% of self-reported unexposed non-smokers and levels corresponding to 
SHS exposure in 74% [31].  
Dipstick  tests  (NicAlert  and  TobacAlert  strips)  were  used  in  urine  and  saliva  for  qualitative 
assessment of cotinine levels. In urine samples both TobacAlert and NicAlert performed poorly at low 
nicotine levels, and cannot be used reliably to indicate a specific level of urine cotinine at the low 
levels found in SHS-exposed people [32]. The specificity of NicAlert in saliva is 95%, its sensitivity 
93%, its positive predictive value 95% and its negative predictive value 93% for verifying the smoking 
status (>10 ng/mL) of self-identified smokers versus non-smokers with gas chromatography-nitrogen 
phosphorus detection as reference standard. In the readings from all five non-smokers exposed to SHS 
(among a total of 45 non-smokers), the NicAlert test was always negative. Thus the method did not 
detect all levels of SHS exposure [33].  
Protein  and  DNA  adducts  are  not  often  used  for  the  detection  of  SHS  exposure.  Due  to  their  
half-life  of  ± 40  days,  urine  NNAL  and  NNAL  glucuronide  [NNAL-O-gluc]  and  [NNAL–n-gluc] 
(metabolites  of  the  carcinogenic  tobacco  specific  nitrosamine  NNK  [4-(methylnitrosaminol)-1- 
(3-pyridyl)-1-butanone]  can  monitor  long  periods  of  exposure  and  are  well  correlated  with  urine 
cotinine levels. In a review of the literature, NNAL and NNAL-glucuronide were the most consistently 
elevated biomarkers in people exposed to SHS [34].  
In urine samples, the levels of 1-hydroxypyrene-O-glucuronide, the major metabolite of pyrene, a 
common polycyclic hydrocarbon, correlated (p = 0.04) with the hours of secondhand exposure in  
non-smokers; poor specificity, however, does not allow them to be used to measure SHS exposure [35]. 
Other carcinogenic products, benzene and 1-3-butadiene, were also measured in air and in body fluids 
of non-smokers [36]  
Biomarkers can allow a valuable quantification of tobacco smoke absorption but can also establish 
the biological plausibility of the epidemiological observations [37].  
3. Exposure to SHS  
Exposure to SHS is indirectly evaluated through studies of air markers or can be measured directly 
by biomarkers of intake. Both can aid in selection of preventive measures (e.g., partial or total smoking 
bans) and assess their efficiency and implementation.  
3.1. Air Markers 
3.1.1. Hospitality venues 
Before  the  smoking  bans  in  hospitality  venues  high  concentrations  of  SHS  were  demonstrated 
mostly by large PM2.5 levels of above the American safety standard of 35 µ g/m
3 per 24 h [38]. This 
was the case for pubs, cafes and bars [39], particularly in pubs frequented by deprived communities 
versus affluent communities [40], but also and even at higher levels in discotheques and at lower levels 
in restaurants and restaurant-cars [39].  
That ventilation fails to control SHS was demonstrated by the high levels of PM2.5 and PPHA in 
pubs despite a per occupant ventilation rate that conformed to the recommendations [10].  Int. J. Environ. Res. Public Health 2011, 8                 
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Even in outdoor dining areas, but at only one meter of a smoker, the PM2.5 levels, although below 
the safety standard, triple during the smoking period. Being under an overhead awning increases the 
average exposure to PM2.5 by around 50% in comparison with the background level [41]. 
The  same  trends  were  observed  when  air  nicotine  (lower  limit  of  detection  0.01  µ g/mL)  was 
detected in a cross-sectional study of hospitality venues in eight European countries: nicotine was 
detected in 97.5% of the samples. The highest median values were observed in discos/pubs, and the 
lowest in restaurants. The concentrations were higher in smoking vs. non-smoking areas (ratio 3.12). 
Most countries had only smoking restrictions or no regulations at all, but in Ireland and Italy, where a 
smoking ban had been implemented, the nicotine concentrations were much lower [42]. There was a 
trend towards lower concentrations in this 2008 study in comparison with the earlier 2005 data in 
hospitality venues [43]. 
In capital cities of Latin America, the highest levels of nicotine were measured in bars, but a median 
concentration  of  0.60  µ g/m
3  nicotine  was  also  detected  in  the  non-smoking  areas  of  restaurants, 
showing that unisolated non-smoking areas are not fully effective in controlling SHS exposure [44].  
PM2.5 concentrations were compared in 32 countries from the five regions of the World Health 
Organization  (WHO).  The  levels  were  7.5  times  higher  in  countries  without  indoor  air  policies 
compared with countries with such policies. The concentrations were also much higher in venues 
where smoking was noticed than in those where it was not; they are linked with the average number of 
cigarettes (or water-pipes) per 100 m
2 [45]. In venues where smoking was noticed, the observed levels 
were well above the WHO quality targets of 10 µ g/m
3 annual mean and 25 µ g/m
3 24h mean [7].  
3.1.2. Hospitals 
Air  nicotine  concentrations  were  quite  dissimilar  in  the  hospitals  of  five  European  cities  in  
2001–2002 (ranging from 0.14 to 4.0 µ g/m
3) [43]. In Latin America, despite restrictions or bans on 
smoking, low levels of nicotine were detected in 95% of hospital samples, with a large range within 
and across hospitals (0.01–1.33 µ g/m
3) [44].  
3.1.3. Aircrafts, airports and train stations 
In-flight air quality measured in ± 250 American aircrafts before the 1989 smoking ban violated the 
PM2.5 federal air quality standards in the cabins by approximately three fold for flight attendants due to 
major deficiencies in the ventilation systems [46]. In seven European cities in 2001–2002, despite 
smoking restrictions in most areas, ranges of air nicotine concentrations were 0.1–5 µ g/m
3 in airports 
and 0.5–10 µ g/m
3 in train stations [43]. 
3.1.4. Motor vehicles 
In  smokers’  vehicles,  median  air  nicotine  concentrations  were  9.6  µ g/m
3,  whereas  there  were  
non-detectable  concentrations  in  non-smokers’  vehicles.  The  increase  was  1.96  fold  per  cigarette 
smoked. The level of air nicotine was higher than in restaurants and bars [47]. In 18 motionless cars, 
windows closed, the average levels of PM2.5 were >3,800 µ g/m
3; with air conditioning, the levels 
decreased to 844 µ g/m
3, and holding the cigarette next to a half-open window, to 223 µ g/m
3 [48].  Int. J. Environ. Res. Public Health 2011, 8                 
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In three stationary cars in Crete, where the outside baseline measurements were 13 µ g/m
3, with a 
cigarette left to burn until it extinguished itself, and without heating/air conditioning, the mean PM2.5 
was between 12,000 and 13,000 µ g/m
3; it decreases significantly with increase in air circulation (from 
windows fully closed, to half open or fully open), and in vehicles with a large interior passenger 
volume [49]. The nicotine level in air sample, surface wipe and dust from used cars for sale was higher 
in 87 smokers’ cars than in 20 non-smokers’ cars. When smokers had imposed a car smoking ban, the 
air nicotine levels were significantly lower, but dust and surface contamination levels remained at 
similar levels. This shows the importance of the issue of ―third hand smoke‖ [50].  
3.1.5. Various public places 
In a review, the weighted means of indoor air nicotine obtained from 13 studies conducted in the 
US before 2003 were as follows: 3 betting establishments: 9.8 µ g/m
3; 2 bowling alleys: 10.5 µ g/m
3;  
2 billiard halls: 13.0 µ g/m
3; 10 bars 31.1 µ g/m
3; 2 bingo parlors: 76.0 µ g/m
3 [51].
 In China, a mean 
nicotine  level  of  7.48  µ g/m
3 was  observed  in  entertainment  establishments  versus  2.17  µ g/m
3  in 
restaurants [52].  
3.1.6. Schools and universities 
In seven European cities, median air nicotine concentration ranged from 0.07 to 0.80 µ g/m
3 in 
schools and from 0.01 to 0.50 µ g/m
3 in universities, with similar data whether or not smoking was 
allowed in a particular area [43]. In Latin America, despite a smoking ban in most countries, nicotine 
was detected in 78% of samples, but at a low median concentration [44]. 
3.1.7. Homes and residences 
Since  the  implementation  of  bans  of  smoking  in  public  places,  homes  have  become  a  major 
contributor to SHS exposure. 
PM2.5 was measured over a 3-day period in nine homes where smoking was allowed and in three 
smoke-free  homes  [53].  PM2.5  levels  in  the  primary  smoking  area  of  the  smoking  homes  were 
significantly higher than in distal areas (84 vs. 63 µ g/m
3). Smoking in only part of the home offers thus 
no complete protection for people anywhere inside the home. In smoke-free homes, PM2.5 levels were 
9  µ g/m
3  lower  than  the  Environmental  Protection  Agency  (EPA)  annual  standard  for  air  quality  
(15 µ g/m
3).  
A partial explanation of the persistence of SHS in homes where a smoker is living but not smoking 
inside  the  home  could  be  the  washout  time  for  residual  tobacco  smoke  from  the  lungs  after  the 
smoker’s last puff , as 10 repeated re-entries of a smoker after the last puff increases the PM2.5 in the 
room from a background of 0.56 µ g/m
3 to 3.32 µg/m
3 [54].  
In the Greater Boston Area, air nicotine concentrations and the air exchange rates were measured in 
49 low-income multi-unit residences. There was a wide range of levels, from the limit of detection to 
26,92 µ g/m
3, with a mean value of 2.20 µ g/m
3. Smoke contamination is not limited to houses with 
smokers,  but  increased  levels  of  nicotine  concentration  were  observed  in  non-smoking  homes, 
suggesting  SHS  infiltration  from  neighboring  units  [55].  PM2.5  levels  measured  through  personal Int. J. Environ. Res. Public Health 2011, 8                 
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monitors  worn  by  407  non-smoking  pregnant  Polish  women  were  higher  when  exposed  to  
>10 cigarettes per day (CPD) (88.8 µ g/m
3) than when exposed to ≤10 CPD (46.3 µ g/m
3) or unexposed 
to SHS (33.9 µ g/m
3) [56].  
3.1.8. Water-pipe smoking 
During laboratory sessions, the levels of PM2.5 in the air increased from 48 µ g/m
3 at background to 
264 µ g/m
3 after water-pipe smoking by 10 individuals, while after smoking 10 cigarettes the levels 
increased from 44 µ g/m
3 to 267 µ g/m
3. Water-pipe smoking thus contributes as much  to SHS as 
cigarette smoking [57].  
3.2. Biomarkers 
3.2.1. General population 
A decrease in SHS exposure has been observed in the USA [58,59]. In the cross-sectional National 
Health  and  Nutrition  Examination  Survey  (NHANES)  surveys  of  the  US  civilian  population  
aged ≥4 years, among non-smokers (serum cotinine ≤ 10 ng/mL), exposure to SHS (defined as a 
detectable serum cotinine level of ≥0.05 ng/mL) declined significantly from 83.9% in 1988–1994 to 
46.4%  in  1999–2004.  The  percentage  of  decline  was  lower  among  the  younger  population  aged  
4–19 years than for those aged ≥20 years, and smaller for the lowest income group compared with the 
higher income groups. This decrease can be linked with the smoking bans and the reduced prevalence 
of active smoking [58].  
The prevalence of serum cotinine levels ≥0.05 ng/mL in the non-smoking US population decreased 
significantly, from 52.5% during 1999–2000 to 40.1% during 2007–2008. Nevertheless, an estimated 
88 million non-smokers aged ≥3 years are still exposed. Children remain among the most exposed [59]. 
Among a nationally representative sample of 4,952 non-smoking employed adults who reported no 
home exposure to cigarette smoke, the geometric mean serum cotinine (ng/mL) ranged from 0.09 for 
farming, foresting and fishing occupations to 0.22 for operators, factory workers, laborers and to 0.47, 
the  highest,  among  waiters  for  the  period  1988-1994,  with  values  decreasing  between  1988  and  
1994 [60].  
In US, with a cut-off point of ≥0.05 ng/mL serum cotinine for adult non-smokers, the prevalence 
rates  of  exposure  to  SHS  in  the  general  population  were  44.9%  nationally  (4,476  subjects  in  the  
2003–2004 survey) and 56.7% in New York City (2004 survey), respectively, contrasting with active 
smoking prevalences of 29.7% and 23.3%, respectively [61].  
Among African-American or Dominican pairs of women and newborns residing in underserved 
neighborhoods of New York City with levels of plasma cotinine <25 ng/mL, 53% of mothers and 49% 
of infants had levels indicative of SHS exposure (≥0.03–<25 ng/mL) [62].  
3.2.2. Hospitality venues 
Twenty four h urine samples were collected on working and non-working days in non-smokers 
working  in  restaurants  and  bars  that  permitted  smoking.  Significant  increases  in  nicotine  +  Int. J. Environ. Res. Public Health 2011, 8                 
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nicotine-glucuronides, cotinine + cotinine N glucuronide and total NNAL were observed during the 
working period [63]. 
In New Zealand hospitality venues, the saliva cotinine concentrations increased more between the 
beginning  and  the  end  of  the  workshift  among  workers  in  premises  allowing  smoking  among 
customers  everywhere  than  in  smoke-free  premises,  and  in  premises  permitting  smoking  only  in 
designated areas [64]. 
In Dakota, USA, after exposure to SHS in three heavily polluted bars, the net mean increases in 
urinary cotinine among eight healthy non-smoking patrons were measured before and estimated after  
6 hours (from the mean of 2 h and 12 h measurements). The post-exposure values in the three bars 
were  4.28  ng/mL,  6.88  ng/mL  and  9.55  ng/mL,  respectively,  above  the  pre-exposure  background 
values [65].  
Prior to the smoking ban, the increase in saliva cotinine was measured after 3-hour exposure among 
non-smokers in bars in New Zealand: the mean increase was 0.66 ng/mL, i.e., ± 8-fold, higher in winter 
than in spring, even in venues that seemed to be smoke-free on direct observation [66].  
In Hong Kong, among 104 workers in catering facilities not exposed outside the workplace, mean 
urinary cotinine levels ranged from 6.4 and 6.1 ng/mL when smoking was not allowed or restricted to 
15.9 ng/mL with unrestricted smoking [67]. 
Urine concentrations of cotinine were measured in 100 non-smoking volunteers before entering a 
Mexican discotheque  and 6 hours after  the  end of the exposure. In  males, pre-exposure levels of 
cotinine  (3.7  ng/mL)  increased  to  49.1  ng/mL  post-exposure  and  in  females  from  2.2  ng/mL  to  
15.7 ng/mL [68].  
A volunteer sample of bar (86%) and restaurant (14%) workers was recruited for a hair nicotine 
prevalence study. SHS exposure at work, at home, in the car or truck and in any other source of regular 
exposure was self-reported. Among 129 non-smokers, the hair nicotine levels were 0.63 ng/mg with no 
exposure, 1.18 ng/mg with one source, 1.32 ng/mg with two and 1.96 ng/mg with three or more; type 
of establishment, bar versus restaurant (p = 0.001) and number of sources (p = 0.007) were the best 
predictors of hair nicotine level. The total variance explained by the model is only 12%. The total 
hours of reported exposure were associated with both the number of sources (p < 0.0001) and hair 
nicotine level (p < 0.0001) [69].  
3.2.3. Casino patrons 
Mean increases in total urine cotinine (0.044 nmol/mg creatinine) and total NNAL (0.018 pmol/mg 
creatinine) were significant (p < 0.001) among non-smoker casino patrons before and after 4 hours stay 
in a casino where smoking was allowed [70].  
3.2.4. Hospital inpatients 
In a public hospital of San Francisco, in 2005–2006, significant exposure to SHS (possibly before 
hospitalization) was demonstrated through measurement of serum cotinine levels in 32% of inpatients 
denying smoking [71].  
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3.2.5. Aircraft 
In flight attendants, before the smoking ban in aircrafts, SHS assessed through cotinine urinary 
dosimetry was estimated to be 14-fold that of the average person. Ventilation declined by 33–60% 
between 1970 and 1987, and massively failed to control SHS air pollution in aircraft cabins [46].  
3.2.6. Home 
In the Health Survey for England, nationally representative samples of children aged 4–15 years  
(n = 13,365) and their parents were interviewed in the home. The proportion of homes where one 
parent was a smoker but that were smoke-free, increased from 21% in 1996 to 37% in 2007, and where 
both parents smoked but were also smoke-free, from 6% to 21%. Most homes with non-smoking 
parents were smoke-free (95% to 98%). The geometric mean saliva cotinine across the years was  
0.22 ng/mL for children with non-smoking parents living in a non-smoking home. When one parent 
was smoking, the mean cotinine levels were 0.37 ng/mL in non-smoking homes and 1.67 where there 
was smoking in the home. For the children with two smoking parents, these values were 0.71 and  
2.46 ng/mL, respectively. Across the years, there was a declining trend in saliva cotinine concentration 
in smoke-free homes for children of smoker or non-smoker parents [72]. 
In Poland, one year after delivery, 46% of children are exposed to SHS as confirmed by urine 
cotinine measurements [73].  
In Spain, in a cohort study of 987 infants, the median urinary cotinine increases 1.4 times when 
father smokes and 3.5 times when mother smokes. In most children considered unexposed to SHS by 
their mother, urine cotinine levels above 1 ng/mL are detected [74].  
Hair cotinine was measured in 104 mother/child pairs. In general, child hair cotinine levels were 
higher  than  maternal  levels  (1.18  ng/mg  versus  0.78  ng/mg,  p  <  0.001).  Levels  in  children  of 
nonsmokers were higher than maternal levels (0.77 ng/mg versus 35 ng/mg, p < 0.001) while levels 
were not different between smokers and their children (1.91 ng/mg versus 1.92 ng/mg, p = 0.978) [75]. 
Geometric means of hair nicotine of pregnant women are the lowest (0.33 ng/mg) when the spouse is 
not smoking (A), intermediate (0.51 ng/mg) when the spouse is a smoker not smoking in the home (B) 
and 0.58 ng/mg when the spouse is smoking in the home (C). Differences between A and B and A and 
C are significant, but not between B and C. Not smoking only in the home is thus inadequate to protect 
completely pregnant women from SHS [76].  
Pregnant  women  frequently  underestimate  their  exposure  to  SHS.  In  a  study  of  698  pregnant 
women reported as non-smokers, 305 (43.7%) claimed not to be exposed to SHS, yet 196 of these 
(64.3%) had plasma cotinine levels above the limit of detection [77].  
Among 114 infants living in homes with parents who smoked, urine total NNAL was detectable in 
67, for whom the number of cigarettes smoked per week in the home or car was significantly higher. 
The mean level of NNAL in the 144 infants was 0.083 pmol/mL, higher than in most other field 
studies of SHS, probably linked to the proximity of infants to parents who smoke [78].  
In families where the pregnant women was neither smoking nor exposed to external sources of SHS, 
and  where  the  father  was  smoking  indoors,  the  hair  nicotine  concentrations  of  the  neonate  are 
significantly higher (p < 0.05) than in the group with non-smoking fathers or fathers smoking only Int. J. Environ. Res. Public Health 2011, 8                 
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outdoors. Paternal smoking inside the home thus produces maternal and fetal intake of SHS [79]. 
Children’s urine cotinine decreased non-significantly in children of mothers receiving counseling to 
reduce children’s secondhand exposure versus a control group of mothers with usual care [80].  
3.2.7. Experimental conditions 
Forty non-smokers were exposed for 4 hours to aged, diluted SHS generated by a smoking machine 
(140  µ g  nicotine/m
3).  Short-term  increases  in  saliva  cotinine  were  similar,  at  approximately  
12 pg/mL/min, among men and women, African-Americans and Whites, suggesting an absence of 
metabolic differences between the groups [26].  
3.2.8. Pets 
Urinary cotinine was detected in 15 domestic dogs from homes where residents smoked at least  
20 CPD for a minimum of 24 months, and not in 15 dogs from homes without smokers. In exposed 
dogs, broncho-alveolar lavage detected an increase in macrophage and lymphocyte population [81].  
Cats from 19 households in which smoking was reported had significantly higher concentrations of 
urine total nicotine (70.4 ng/mL),  total cotinine (8.53 ng/mL) and total  NNAL (0.0562 pmol/mL) 
compared  with  cats  that  lived  in  42  households  in  which  there  was  no  smoking.  (4.89  ng/mL,  
0.74 ng/mL and 0.0182 pmol/mL, respectively [82]. The risks incurred by their pets can sometimes 
push smokers towards cessation. 
4. Effects of Smoking Bans  
Air and biomarkers measurements allow both the effectiveness of the smoking bans and the level of 
their effective implementation to be quantified. 
4.1. Effects on Validated Air Quality 
4.1.1. Hospitality venues 
Major improvements were observed in hospitality venues of many countries after the introduction 
of smoking bans. The levels of PM2.5 were measured before and after the 2003 New York State law on 
smoke-free  workplaces  in  a  purposeful  sample  of  20  hospitality  venues.  After  the  ban,  a  general 
decrease of 84% of PM2.5 was observed. In bars and restaurants where smoking was occurring at 
baseline, a decrease of 96% was observed (towards mean values below the security standard). In the 
restaurant  portion  of  the  two  bar-restaurants  initially  allowing  smoking  in  the  bar  but  not  in  the 
restaurant section, the decrease averaged 58% in the restaurant section. In four large recreation venues 
(two bowling alleys, a pool hall and a bingo hall) there was a 76% decrease [83].  
In Wilmington, Delaware, where the smoking ban was extended in 2002 to hospitality venues, the 
air PM3.5 and PPAH were measured in a casino, six bars and a pool hall/bar where smoking was 
initially allowed. The average prelaw values of PM3.5 were 231 µ g/m
3 vs. 9.5 µ g/m
3 outdoors and  
134 ng/m
3 PPAH vs. 21 ng/m
3 outdoors. Mean post-ban values are indistinguishable from outdoors. 
Ventilation or air cleaning would be unable to obtain such a decrease [9].  Int. J. Environ. Res. Public Health 2011, 8                 
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After the smoke-free workplace law in Boston, MA, the PM3.5 decreased by 23-fold (to an average 
of 7.7 µ g/m
3) in six pubs, and the PPAH by nearly 10 times, to 6.32 ng/m
3. PM reached the levels of 
good  air  quality  in  6/7  venues,  and  PPAH  levels  were  lower  than  outdoors  in  the  seven  
pubs [10].  
The effects of the Irish smoking ban in bars, restaurants, cafes and hotels (excluding bedrooms, 
outdoor areas and properly designed smoking shelters) were assessed via air nicotine measurements. 
There was an 83% reduction in air nicotine concentration from a median 35.5 µ g/m
3 to 5.95 µ g/m
3  
(p < 0.001). Validated exposure and the number of observed hours of exposure were thus reduced but 
not totally eliminated after this partial ban [84]. In 42 Irish pubs, a PM2.5 reduction of 83%  was 
observed after the ban. In 26 pubs, benzene concentrations were reduced by 80.2% [85].  
In the English hospitality industry, indoor PM2.5 concentrations decreased by 95% from 217 µ g/m
3 
at baseline to 11 µ g/m
3 one month after the ban [86]. In a random selection of 41 pubs in two Scottish 
cities, the levels of PM2.5 averaged 246 µ g/m
3 before and 20 µ g/m
3 after the ban. In most pubs, the 
level of PM2.5 became comparable with the outside ambient air PM2.5 level. The levels of benzene 
decreased also from 18.8 µg/m
3 preban (above the security limit of 5 µg/m
3) to 3.6 µ g/m
3 postban. 
Reductions were observed in all post-ban visits, showing high compliance with the ban [87]. 
Full shift PM2.5 geometric means were measured with personal PM2.5 monitors in six bar workers in 
Scotland. They fell from 202 µ g/m
3 pre-ban to 28 µ g/m
3 post-ban, meaning (after log analysis) an 
average reduction of 86% [88].  
In  selected  restaurants  and  bars  with  a  serving  area  larger  than  100  m
2  in  Finnish  cities, 
measurements were conducted before and after enforcement of the act imposing smoke-free zones in 
such  venues.  The  overall  air  nicotine  concentrations  decreased  in  10  of  18  establishments.  The 
geometric mean nicotine concentration moved in restaurants from 0.7 µ g/m
3 to 0.6 µg/m
3, in bars and 
taverns from 10.6 µ g/m
3 to 12.7 µg/m
3, in discos and nightclubs from 15.2 µ g/m
3 to 8.1 µ g/m
3. In the 
smoke-free  sections,  the  concentrations  were  practically  unchanged  (2.9  µ g/m
3).  The  small 
improvements in some sites were linked with increased ventilation, but physical barriers separating 
smoking from smoke-free areas are thus required to obtain a major reduction in SHS [89].  
In 13 Norwegian bars and restaurants, the arithmetic mean concentration of air nicotine declined 
from 28.3 µg/m
3 to 0.6 µ g/m
3 after the total smoking ban. Total dust declined from 262 µ g/m
3 to  
77 µ g/m
3 [90].  
In nine Swedish communities (bingo halls, casinos, bars and restaurants), exposure above the air 
nicotine cut-off level chosen to identify possible health risk (<0.5 µ g/m
3) existed in 87% before and 
22% after the smoking ban; the pre-ban exposure levels were highest in bingo halls and casinos [91].  
In Australia, where an indoor smoking ban was promulgated, in a convenience sample of pubs and 
bars that had at least one indoor area with an adjacent semi-enclosed eating area, PM2.5 concentrations 
were reduced indoors by 65% (p = 0.004) and outdoors by 38.8% (p = 0.037) after the ban. However, 
after adjustment, a 100% post-ban increase in geometric mean outdoor PM2.5 was associated with a 
36.1% increase in geometric indoor PM2.5, showing that the air quality in smoke-free indoor areas may 
be compromised by smoking in adjacent outdoor areas [92].  
The  indoor  air  quality  was  compared  by  measuring  PM2.5  before  and  after  enforcement  of  a 
smoking ban in Italy in 40 public places (bars, pubs, restaurants and game rooms). PM2.5 decreased Int. J. Environ. Res. Public Health 2011, 8                 
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from 119.3 µ g/m
3 to 38.2 µ g/m
3 after 3 months (p < 0.005) and to 43.3 µg/m
3 one year later. The mean 
outdoor measurements of PM2.5 were 20.8 three months post-law and 27.2 one year post-law [93].  
4.1.2. Prisons 
In 22 dormitory and common areas in six North Carolina prisons, the PM2.5 levels decreased by on 
average 77% after the indoor smoking ban [94]. This is particularly important, as the prevalence of 
tobacco use is much higher among inmates and prison staff than in the general population. 
4.1.3. Public places, industrial service sector and office workplaces 
In eight Finnish public and private workplaces, median indoor airborne nicotine concentrations 
decreased from 0.9 µ g/m
3 before to 0.1 µ g/m
3 one year after and then remained unchanged 3 years 
after implementation of the national smoke-free legislation [95].  
In  Montevideo,  Uruguay,  a  middle  income  country,  the  median  air  nicotine  concentrations  of  
100–103 indoor samples were 0.75 µ g/m
3 before compared to 0.07 µ g/m
3 after the legislation, but with 
a large overlap of the interquartile rate (IQR) between the two periods. The overall reduction was 91% 
after adjustment for room volume and ventilation. The greatest reduction was observed in schools 
(97%),  followed  by  airports  (94%),  hospitals  (89%),  local  government  buildings  (86%)  and 
restaurants/bars (81%). The reason for the much lower overall air nicotine concentration in Uruguay 
versus other countries is not mentioned, but could be due to the selection process or the differences in 
prevalence of active smoking or increased ventilation in warm countries and the different patterns of 
active smoking [96].  
4.1.4. Contrast between countries with and without smoking bans 
The  air  quality  differences  of  hospitality  premises  between  a  country  with  (Italy)  and  without 
(Austria) a smoking ban was assessed before and 2 years after the introduction of the Italian smoking 
ban in respectively 28 and 19 hospitality premises. Median airborne nicotine concentrations decreased 
from 8.86 µ g/m
3 to 0.01 µ g/m
3 in Italy (p < 0.001) and, in contrast, increased from 11.00 µ g/m
3 to 
15.76 µ g/m
3 in Austria, a non-significant increase [97].  
4.2. Effects of Smoking Bans on Biomarkers of SHS 
Effectiveness and implementation of smoking bans can be measured through direct comparison of 
biomarkers  pre-  and  post  ban  in  the  same  areas,  and  can  also  be  estimated  through  indirect 
simultaneous comparisons of biomarkers in areas with and without bans (with possible bias linked 
with other inter-area differences). 
4.2.1. General population  
4.2.1.1. Pre- and post comparisons 
From October 1988 through December 2002, in a sample of 29,849 individuals representative of the 
US non-institutionalized civilian population ≥ 4 years of age, a substantial decline of approximately Int. J. Environ. Res. Public Health 2011, 8                 
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70%  in  serum  cotinine  concentration  was  observed  in  non  users  of  tobacco.  Serum  cotinine 
concentrations ≥ 0.05 ng/mL were observed in 88% of non-smokers between 1988 and 1991, and in 
only 43% in 2000–2002. Increase in smoke-free policies and to a small degree reductions in smoking 
prevalence may have contributed to the decline of the exposure of non-smokers to SHS. 
The fact that smoke-free bans are not ―applicable‖ to home and car exposure could explain the 
higher  serum  concentration  in  children,  while  higher  SHS  exposure  also  seems  responsible  in  
non-Hispanic blacks [58].  
In  the  general  population  of  New  York,  saliva  cotinine  levels  decreased  by  47.5%  among  
non-smoking  adults  after  implementation  of  the  2003  New  York  state  ban  on  smoking  in  indoor 
workplaces and public places [98].  
4.2.1.2. Comparisons between areas 
In the US, SHS exposure, defined as serum cotinine ≥ 0.05 ng/mL, was determined from 5,866 non 
smoking adults categorized by their level of coverage by a smoke-free law. The odds of exposure was 
much  lower  with  extensive  coverage  (0.10  in  men  and  0.19  in  women)  and  lower  with  limited 
coverage (0.57 in men and 0.90 in women) than with no coverage, used as reference value [99].  
4.2.2. Hospitality workers 
4.2.2.1. Pre- and post comparisons 
In a pre-post follow-up study, saliva cotinine specimens were available among 24 non-smoking 
workers in restaurants, bars and bowling facilities followed up until 12 months after the New York 
smoke-free law. Saliva cotinine concentration decreased from 3.6 ng/mL (95% confidence interval [CI] 
2.6–4.7) to 0.8 ng/mL (95% CI 0.4–1.2), suggesting compliance with the law [100]. 
The  effects  of  the  Lexington  smoke-free  law  covering  all  buildings  open  to  the  public  were 
investigated respectively before and 3 months after the law was implemented in a convenience sample 
of 105 workers (including 40 active smokers), of whom 92 worked in restaurants and 13 in bars. The 
geometric mean of hair nicotine among bar-workers was 4.51 ng/mg before and 1.06 ng/mg 3 months 
post-law, and in the restaurant cohort 1.54 ng/mg before and 1.20 ng/mg after. After adjustment for 
CPD, the decline from pre- to post-law was significant for bar workers (p = 0.0004), but marginal 
among restaurant workers (p = 0.07). Subject retention was a problem, as only 71 of the 105 initial 
participants were followed up at 3 months [101]. 
In  Minnesota  communities,  among  24  non-smokers  working  in  hospitality  venues  (12  bars,  
6 restaurants, 5 bowling alleys and one unknown workplace) and living in non-smoking households, 
the median percentage decrease after the ban was very significant in urine as well for total cotinine 
(83.3%) as for total NNAL (76.6%). Levels of total NNAL/mg creatinine were significantly correlated 
with the number of hours worked in the smoking section (r = 0.43; p < 0.05) [102].  
In  England,  among  75  non-smoking  employees  of  the  hospitality  industry,  saliva  cotinine  was 
reduced from 3.6 ng/mL one month before the smoke-free legislation to 0.9 ng/mL one month after its 
implementation (p < 0.001) [86].  Int. J. Environ. Res. Public Health 2011, 8                 
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The same trend was observed in Norway among 25 non-snuffing non-smoker employees in bars and 
restaurants  from  a  geometric  mean  urine  cotinine  concentration  of  9.5  µ g/g  creatinine  preban  to  
1.4 µ g/g creatinine post-ban (p < 0.01). However, there was also a reduction among 29 non-snuffing 
smokers, from 1,444 µ g/g creatinine to 688 µ g/g creatinine (p < 0.05), suggesting a reduction in active 
smoking after the intervention [90].  
The impact of the Irish smoking ban on the saliva cotinine concentration in a cohort of 35 workers 
from 15 city hotels translated into a 69% decrease from a median value of 1.6 ng/mL to 0.5 ng/mL  
(p < 0.0005), showing the persistence of limited exposure. Self-reported exposure to SHS nevertheless 
decreased from a median of 30 hours a week to zero [84].  
In Italy, the concentration of urine cotinine among non-smoker workers in 40 hospitality venues 
decreased from 17.8 ng/mL to 5.5 ng/mL 3 months after (p < 0.0001) and to 3.7 ng/mL 12 months 
after (p < 0.0001) the smoking ban, together with a contemporaneous reduction in indoor fine and 
ultrafine particles [93].  
4.2.2.2. Inter-area comparisons 
The effects of the New York clean indoor legislation appear also in a pre-postlaw comparison of 
non-smoking hospitality workers compared with American Indian casino workers exempt from the law. 
The median urine cotinine decreased from 4.93 ng/mL prelaw to 0.30 post-law (p < 0.01) among the 
former,  but  remained  at  a  higher  level  in  the  latter  (8.40  vs.  6.49).  Urine  cotinine  levels  were 
significantly related with self-reported numbers of exposures and number of days exposed [103].  
In Oregon, the influence of exposure was assessed among CO-validated non-smokers employed in 
52 bars or restaurants where smoking was allowed or in 32 where smoking was prohibited by local 
ordinances. After a workshift of 4 hours, among workers exposed to workplace SHS, the odds of 
having a detectable urine level of total NNAL were almost six times higher than for protected workers 
(aOR = 5.66; p = 0.005) . The same was true for detectable levels of urine nicotine (aOR = 109.01;  
p < 0.001) and cotinine (aOR = 95.21; p < 0.001). The post workshift mean level of urine total NNAL, 
nicotine  and  cotinine  was  0.02  pmol/mL,  1.39  ng/mL  and  1.4  ng/mL  for  protected  workers  vs.  
0.04  pmol/mL,  44.36  ng/mL  and  20.20  ng/mL  for  exposed  workers.  Each  hour  of  self-reported 
exposure to SHS was associated with an increase of 6% in total NNAL, of 33% in total nicotine and of 
12% in total cotinine [104].  
Following the smoke-free Spanish law of 2006, in bars and restaurants >100 m
2, the proprietors 
were still allowed to provide a separate, independently ventilated smoking area comprising less than 
30% of the total floor area. For venues with a floor area <100 m
2, the owner could choose between a 
totally non smoke-free  or  a  totally smoke-free  venue (in fact  only 10–20%  of those  venues were 
smoke-free). In Portugal and Andorra, no smoking ban was in effect at the time of the study. In a 
convenience sample in Spain, Portugal and Andorra, hospitality venues were recruited based on their 
size (< or >100 m
2) and area: these venues were pubs, bars, restaurants and discos; 117 non-smoking 
workers completed the study in Spain and 20 in Portugal and Andorra. Non-smokers were defined as 
self-reported never or former smokers, with a saliva cotinine concentration <20 ng/mL, a high cut-off 
level justified by the potentially high exposure to SHS in hospitality venues. Before the Spanish law, 
the median stimulated saliva cotinine concentrations among non-smokers were 2.0 ng/mL in Spain and Int. J. Environ. Res. Public Health 2011, 8                 
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1.2 ng/mL in Portugal and Andorra (p < 0.01). In Spain, in venues where smoking was totally banned, 
the  median  saliva  cotinine  decreased  from  1.6  ng/mL  before  the  ban  to  0.5  ng/mL  after  the  ban  
(p < 0.01), a 56.6% reduction; in 22 venues where smoking was permitted in designated areas, from 
1.8 ng/mL to 1.1 ng/mL (p = 0.0618), a non-significant 31.9% reduction; in 63 venues where smoking 
was permitted throughout the premises, saliva cotinine remained stable from 2.5 ng/mL to 2.6 ng/mL  
(p  =  0.475).  In  Portugal  and  Andorra,  the  median  saliva  cotinine  remained  unchanged  before  
(1.2 ng/mL) and after (1.2 ng/mL) the Spanish ban. Self-reported duration of SHS exposure decreased 
by  100%  in  Spanish  venues  where  smoking  was  totally  banned  (p  <  0.01),  whereas  a  borderline 
significant decrease (from 8 hours median exposure per day to 1 hour per day; p = 0.055) was observed 
in venues where smoking was partially permitted. Median duration of exposure increased significantly 
in venues with no smoking restrictions (from 8.0 to 10.0; p < 0.01). 
In Portugal and Andorra, duration of exposure to SHS in hospitality venues remained unchanged, at 
8 hours. SHS exposure outside the workplace decreased in Spain regardless of the type of postban 
regulation (between −16% and −54.6%) but increased in Portugal and Andorra (+54.2%) [105].  
4.2.3. Bar workers 
4.2.3.1. Pre-and post comparisons 
In 73 non smoking barmen working in Dublin pubs, there was a 79% reduction in exhaled breath 
CO and a 81% reduction in saliva cotinine after a total workplace smoking ban, together with a 90% 
decrease in total exposure at work, and a 42% decrease outside of work [85].  
The same type of comparison was conducted in Canada between Toronto (79 eligible non-smoking 
bar  workers),  where  a  smoke-free  bylaw  was  enacted  and  Windsor  (49  eligible  non-smoking  bar 
workers), with no bylaw change. Urinary cotinine levels decreased from 24.2 ng/mL to 7.8 ng/mL in 
Toronto immediately after the ban, with the reduction sustained 1, 2 and 9 months post-ban, while 
there was no change among Windsor bar workers. The compliance with the ban was both high and 
persistent [106].  
Prior to the introduction of the Scottish smoke-free legislation and 2 months and 1 year after its 
implementation,  saliva  samples  were  collected  in  their  places  of  work  in  191  bar  workers.  In  
non-smokers, the saliva cotinine level decreased from 2.94 ng/mL to 0.41 ng/mL at 1 year (a reduction 
of 89% in non-smokers’ cotinine levels). Among smokers, a reduction of 12% was recorded during the 
same period, probably reflecting both reduction of exposure to SHS at work and a decrease in active 
smoking [88].  
The same trend was observed for benzene and 1-3 butadiene levels, for which the average dose after 
a standard exposure of 3 hours in Irish pubs diminished by 91 and 95%, respectively, after the ban [36].  
4.2.3.2. Inter-area comparisons 
In  the  Republic  of  Ireland,  among  158  non-smoker  bar  staff,  a  decrease  in  saliva  nicotine 
concentration was observed before and after legislation for smoke-free workplaces (from 29.0 nmol/L 
to 5.1 nmol/L), while in Northern Ireland, without a ban, over the same period the decrease was much 
more limited (25.3 nmol/L to 20.4 nmol/L) and not significant, with overlapping of the confidence Int. J. Environ. Res. Public Health 2011, 8                 
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intervals.  After  adjustment,  the  decline  was  twice  as  great  in  the  Republic  than  in  Northern  
Ireland [107].  
4.2.4. Bar patrons 
In Dakota, USA, in three heavily polluted bars, the net mean increases in urine cotinine among 
eight healthy non-smoking volunteers were measured before and estimated after a 6-hour exposure 
(from the mean of 2 h and 12 h measurements). The post-exposure values in the three bars were  
4.28 ng/mL, 6.88 ng/mL and 9.55 ng/mL above the pre-exposure background values [65]  
Saliva cotinine levels were measured among non-smoking volunteers before and after a 3-hour visit 
to 30 randomly selected bars in New Zealand. Before the comprehensive smoke-free legislation, there 
was an average increase in saliva cotinine of 0.66  ng/mL. After the law change, the mean saliva 
cotinine increase was much lower, but persisted at 0.08 ng/mL, despite quasi total compliance with the 
law (only 1 lit cigarette observed in 30 visits) [108].  
4.2.5. Homes 
Since  the  smoking  bans  in  many  countries,  the  home  has  become  a  major  source  of  exposure  
to SHS. In Scottish adult non-smokers from non-smoking households, geometric mean saliva cotinine 
concentrations  fell  by  49%  (from  0.35  ng/mL  to  0.18  ng/mL,  p  <  0.001)  within  1  year  after 
implementation of the smoke-free legislation in enclosed public places and workplaces. A smaller 
(16%) fall in cotinine concentration in non-smokers from smoking households was not statistically 
significant. The reduction in self-reported exposure to SHS was clear in public places, but not in 
homes and cars [109].  
4.2.6. Adolescents and children 
In a national cross-sectional survey of the US population, serum cotinine levels were available for 
11,486 non-smoking children and adolescents (3–19 years) from 117 survey locations with extensive 
versus no coverage by a smoke-free law. Among those without home SHS exposure, in a county with 
extensive  coverage  of  a  smoke-free  air  law,  the  adjusted  prevalence  of  detectable  cotinine  was  
0.61 times lower and the geometric mean 0.57 times lower compared with children and adolescents 
from counties without a smoke-free air law. In children and adolescents with home SHS exposure, 
after adjustment for covariables, the differences between counties with or without smoke-free air laws 
was no longer observed [110].  
In a nationally representative cross-sectional survey of ± 2,500 children in Scotland, the geometric 
mean saliva cotinine concentrations in non-smoking children fell from 0.36 ng/mL to 0.22 ng/mL after 
the introduction of the smoke-free legislation (a 39% reduction). The extent of the fall was statistically 
significant  only  among  pupils  living  in  households  in  which  neither  parent  figure  smoked  (from  
0.14 ng/mL to 0.07 ng/mL) and among pupils in households in which only the father figure smoked 
(from 0.57 ng/mL to 0.32 ng/mL) [111].  Int. J. Environ. Res. Public Health 2011, 8                 
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In Australia, feedback to parents of asthmatic children of the results of the  urinary cotinine to 
creatinine level of their children did not significantly change the prevalence of smoking bans at home 
or in the car, nor the daily consumption of cigarettes or consumption in front of the child [112].  
5. Health Effects of Exposure to SHS 
The health effects of exposure to SHS concern the general population, hospitality workers (for 
whom exemptions from the smoking bans are frequently considered), non hospitality workers  and 
finally children (as smoking bans do not concern private housing). The types of effects are disease 
symptoms, disease prevalence and issues, hospitalization rates for SHS exposure related diseases and 
biological data possibly related to exposure-related diseases. 
As  the  reader’s  interest  is  frequently  disease-oriented,  the  main  exposure-related  diseases,  
i.e., cardiovascular, respiratory diseases in adults and children, fertility and pregnancy, sudden infant 
death syndrome, cancers, neuropsychiatric diseases and genotoxicity, will be considered successively.  
5.1. Cardiovascular Diseases  
In 20.8% of a nationally representative sample of 13,443 English and Scottish adults, high levels of 
saliva cotinine (0.71–14.99 ng/mL) were observed in non-smokers. After a mean follow-up of 8 years, 
these were associated with all-cause deaths (age adjusted hazard ratio [HR] 1.25 [95% CI 1.02–1.53)] 
and cardiovascular deaths (adj HR 1.21 [95% CI 0.85–1.73)]. High SHS was also associated with 
elevated C-reactive protein (CRP), which contributes to explaining the association between SHS and 
deaths due to cardiovascular disease (CVD) [113].  
Admission serum cotinine concentrations were measured in consecutive patients admitted to nine 
Scottish hospitals over 23 months. Among 1,261 never smokers, within 30 days, 50 (4%) had died and 
35 (3%) had had a non-fatal myocardial infarction. All-cause death increased from 2.1% in those with 
cotinine ≤0.10 ng/mL to 7.5% in those with cotinine >0.9 ng/mL (χ
2 test for trend p < 0.001). This 
difference persisted after adjustment for confounders (adj OR for cotinine >0.9 ng/mL = 4.80 [95% CI 
1.96–11.83]; p = 0.003). The same trend was observed for death, cardiovascular death, or myocardial 
infarction.  SHS  exposure  is  thus  associated  with  worse  early  prognosis  after  acute  coronary  
syndrome [114].  
From the 10-month period preceding the passage of the Scottish smoking ban (2006) to the same 
period the next year, among all patients admitted with acute coronary syndrome in nine hospitals, there 
was a decrease in the geometric mean concentrations of serum cotinine among never smokers from 
0.68 ng/mL to 0.56 ng/mL (p < 0.001), and a 21% reduction in the number of admissions for acute 
coronary syndrome, together with a self-reported decrease in the weekly duration of exposure to SHS. 
Reductions in admissions for acute coronary syndrome were also observed among former smokers 
(19%) and smokers (14%), while the number of deaths among patients with acute coronary syndrome 
who were not admitted to the hospital decreased by 6%. These reductions contrast with the smaller 
overall reduction in hospital admissions of 4% in England (where such legislation did not exist) during 
the same period, and with the 3% mean annual decrease in admissions in Scotland during the decade 
preceding the study [115].  Int. J. Environ. Res. Public Health 2011, 8                 
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In Rome, Italy, acute coronary events were compared between the pre- and post-legislation period, 
taking into account several time-related potential confounders, including PM10 air pollution. The PM10 
concentration  decreased,  but  not  significantly,  between  the  year  before  and  after  the  ban.  The  
age-standardized  rate  ratios  of  acute  coronary  events  (defined  as  hospitalization  records  of  acute 
coronary events + other out of hospital deaths due to ischemic heart disease from the mortality register) 
were 0.89 (95% CI 0.85–0.93) post-smoking ban versus pre-smoking in the 35–64 years age group and  
0.92  (95%  CI  0.88–0.97)  in  the  65–74  years  age  group,  but  1.02  (95%  CI  0.98–1.07)  in  the  
75–84 years age group. After simultaneous adjustment for both time trends and hospitalization rates, 
the results become borderline in the youngest age group (RR 0.94; 95% CI 0.89–1.01) but remain 
significant in the 65–74 olds (RR 0.90; 95% CI 0.84–0.96). It remains uncertain whether these limited 
effects (11.2% reduction in the population aged 35–64 years and 7.9% in those aged 65–74 years) are 
effectively linked with the smoking ban or with the decrease in active smoking suggested by the 
reduction  in  cigarette  sales  in  2005,  or  with  other,  perhaps  not  controlled  factors.  The  level  of 
implementation of the law was not discussed in this study [116].  
In  US,  the  cross-sectional  relation  between  SHS  exposure  and  recognized  biomarkers  of  heart 
disease risk was investigated among 5,599 never smoking adults (serum cotinine levels ≤15 ng/mL) 
from the third (1988–1991; 1991–1994) national representative examination survey. Serum cotinine 
(threshold of detection 0.05 ng/mL) was not detectable in 18% of the subjects; the other subjects were 
distributed  into  low  (0.05–0.215  ng/mL)  and  high  cotinine  levels  (0.215–15  ng/mL).  Levels  of 
fibrinogen and homocystein were significantly higher in people with detectable serum cotinine versus 
those without (9–10 mg/dL, p = 0.03 and 0.8 µmol/L, p < 0.001) higher respectively, but were not 
statistically different between low and high cotinine levels. White blood cell (WBC) counts decreased 
only for high cotinine levels. CRP did not increase in relation to cotinine. This lack of association 
between cotinine and CRP could be attributed to the low sensitivity laboratory method used for CRP in 
this  survey.  Among  4,990  current  active  smokers,  an  adjusted  mean  increase  of  29.2  mg/dL  of 
fibrinogen and 1.8 µ mol/L of homocystein was observed in comparison with never smokers without 
detectable  cotinine.  The  apparent  effects  of  SHS  on  fibrinogen  and  homocystein,  markers  of 
cardiovascular risk, in non-smokers were approximately one third to one half those observed in active 
smokers, while cotinine levels of passive smokers were only ≈ 0.1% of those of active smokers. These 
disproportionate associations fit the epidemiological evidence of a similar disproportionate association 
of  SHS  exposure  and  active  smoking  with  coronary  heart  disease  risk.  SHS  is  thus  an  important 
avoidable cause of cardiovascular disease [117]  
In  the  US  NHANES  (1999–2002),  in  non-smoking  children  and  adolescents  aged  6–18  years, 
multiple  regression  analysis  indicated  that  a  change  in  serum  cotinine  level  of  0.5  ng/mL  was 
associated with a 0.96 mg/dL change in CRP (95% CI 0.93–1.00) even after adjustment. There is thus 
a significant association between serum cotinine and elevated serum CRP [118]. 
5.2. Respiratory Symptoms and Diseases in Adults 
Experimental exposure to one hour SHS (set at bar/restaurant levels) by 16 voluntary non-smoking 
adults is followed by a mean decrease in FEV1 (forced expiratory volume in one second) from 4.3 L to 
3.8 L and of FEV1/FVC (forced vital capacity) from 0.9 to 0.8 (p < 0.05) immediately after exposure, Int. J. Environ. Res. Public Health 2011, 8                 
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but by a return to baseline values after 3 hours. Serum cotinine increased from 8.9 ng/mL before 
exposure to 35.5 ng/mL 3 hours after exposure. This lag between spirometric and cotinine data is due 
to  the  duration  of  metabolism  from  nicotine  to  cotinine.  Other  inflammatory  cytokines  are  also 
increased after 3 hours in contrast with the return to the initial spirometric values at that moment [119]. 
The impact of smoking policy on respiratory health was assessed among food and beverage servers 
residing in the Vancouver (Canada) area. Acute and chronic respiratory symptoms were the most 
prevalent where smoking was allowed, less prevalent where smoking was partially restricted and still 
less prevalent where it was restricted in 100% of the workplaces. The FEV1/FVC ratio was lower 
(77.8%) in facilities where smoking was permitted than where it was prohibited (81.1%) (p = 0.04). In 
a parallel fashion with this clinical evolution, in a subset of 88 workers, the geometric mean of hair 
cotinine was 1.4 ng/mg for those working in facilities where smoking was prohibited, 4.6 ng/mg with 
partial restriction and 5.4 ng/mg with no restriction (p = 0.01). In the small subset of workers who 
underwent spirometric and cotinine measurements, there was no relationship between lung spirometry 
and hair nicotine levels [120].  
In  public  places  in  Scotland,  concurrently  with  a  decrease  in  serum  cotinine  levels  in  
77 non-smoking bar workers, the prevalence of respiratory and sensory symptoms decreased from 
79.2% before the smoke-free policy to 53.2% one month after the ban (change 82%; p < 0.001) and to 
46.8% 2 months after. FEV1 increased from 96.6% predicted to 104.8% predicted after 1 month and to 
101.7% after 2 months (change 5.1%; p = 0.002). Among the asthmatic bar workers, exhaled nitric 
oxide, a marker of inflammation, decreased from 34.3 parts per billion (ppb) to 27.4 ppb one month 
after  the  ban  (an  0.8-fold  change;  p  =  0.04).  Smoke-free  legislation  is  thus  associated  with  early 
improvements  in  symptoms,  minimal  increases  in  spirometric  values  and  decrease  of  
inflammation [121].  
Full respiratory function tests were performed on 73 barmen before and after the Irish smoking ban. 
Among non-smokers, even if significant, the postban increase in flow value measurements remained 
very  limited,  and  the  diffusion  capacity  for  carbon  monoxide  (DLCO),  as  expected,  remained 
unchanged, while among current smokers, practically all parameters were not significantly different 
between pre- and post-ban periods. The decrease in prevalence of cough and phlegm was significant 
and relevant in non-smokers, but not in current smokers. Symptoms and spirometric values evolve 
concurrently with saliva cotinine measurements [85].  
In a longitudinal study of a cohort of 77 non-smoking adults with chronic obstructive pulmonary 
disease  (COPD)  in  the  US,  higher  levels  of  SHS  exposure,  as  measured  by  urine  cotinine,  were 
marginally associated with worse COPD severity (mean score increment 4.7 points [95% CI −0.1–9.4;  
p = 0.054]). SHS exposure thus seems to aggravate the symptoms of COPD, even after cessation of 
active smoking [122].  
In Scotland, among 148 patients with severe COPD (among them 39 current smokers), the symptom 
burden was worse in households with increased PM2.5, especially among current smokers [123].  
In Sweden, before the ban, 87% of non-smoking hospitality workers were exposed to air nicotine 
levels of ≥0.5 µg/m
3, and 22% after the ban, a relative risk of 0.25 (95% CI 0.15–0.41).There was a 
reduction of ± 50% in respiratory and sensory symptoms, but no notable change in lung function [91].  
Among 72 current biologically verified non-smokers in a cohort study of COPD, the increased 
levels of urine NNAL-to-creatinine ratio (a marker of long-term SHS) were associated with greater Int. J. Environ. Res. Public Health 2011, 8                 
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COPD  severity  (mean  score  increase  1.7  points,  p  =  0.0003)  for  each  interquartile  increment  of 
NNAL/creatinine  ratio,  after  adjustment  for  demographic  data  and  past  smoking.  They  were  also 
related to more severe dyspnoea and more restricted activity (p ≤ 0.05). NNAL, frequently used as a 
marker of lung carcinogenesis, can thus also be a good long-term biomarker of SHS, showing greater 
impact on the severity of COPD than cotinine, a short-term biomarker [124].  
In Spain [105], 12 months after the smoking ban, concurrently with a decrease in saliva cotinine 
and hours of SHS exposure, the prevalence of cough and phlegm considered together decreased from 
40.6%  to  15.6%  (p  <  0.05)  in  totally  non-smoking  venues.  The  prevalence  of  any  respiratory 
symptoms also decreased post-ban in completely smoke-free venues (from 56.2 to 38.1; p = 0.012), but 
not where smoking was allowed in some (p = 0.625) or all (p = 0.774) of the premises. In Portugal and 
Andorra, with no smoking ban, the prevalence of any respiratory symptoms was not significantly 
different between the two periods (p = 0.07). This study shows that in Spanish venues where smoking 
was allowed (at least in theory) in physically separated areas, workers still complained of respiratory 
symptoms. Even in venues where smoking was totally banned, despite a major decrease, the median 
saliva  cotinine  concentration  (0.50  ng/mL)  was  still  above  the  acceptable  levels  of  risk  
(i.e., 0.14 ng/mL [125]).  
5.3. Low Respiratory Illnesses in Infancy and Early Childhood 
In the 2006 US Surgeon General Report, among the large number of papers allowing a causal 
relationship to be inferred between SHS exposure after birth and lower respiratory illness in infants 
and children, middle ear disease in children, respiratory symptoms among children of school age, ever 
having asthma among children of school age and a lower level of lung function during childhood, most 
concern self-report exposures and only a minority refer to air or biomarkers of exposure [2]. 
Recent publications show a relationship between biomarkers, asthma and co-morbidities among 
young asthma patients. In a low-socioeconomic UK community based cross-sectional study, salivary 
cotinine levels were significantly increased in children with doctor-diagnosed asthma compared to 
those  without  (p  =  0.002);  cotinine  validated  exposure  levels  were  also  associated  with  doctor 
validated asthma (Adj OR 1.8; CI 1.4–2.5) [126]. 
Among 222 children in whom asthma was diagnosed by the primary care giver, SHS exposure in 
and  outside  the  home  was  validated  by  cotinine  in  serum  and  hair,  while  the  level  of  PM5  was 
measured at home. Despite lower reported exposure to SHS at home (14.9 vs. 18.7 CPD), with lower 
levels  of  PM5  in  houses,  the  levels  of  serum  and  hair  cotinine  were  significantly  higher  among  
African-American children than among white children (1.41 ng/mL vs. 0.97 and 0.25 vs. 0.07 ng/mg, 
respectively), a difference only explained partially by housing volume [127]. The presence of a strict 
household  smoking  ban  (confirmed  by  child  cotinine  assays)  vastly  reduced  SHS  exposure  in  91 
children with asthma matched with 91 healthy children [128]. 
Among  children  with  asthma,  exposure  to  SHS  (measured  as  serum  cotinine  levels)  was 
significantly  associated  with  sleep  problems  (longer  sleep-onset  delay,  sleep-disordered  breathing  
(p = 0.02), parasomnias (p = 0.002) and overall sleep disturbance (p = 0.0002) [129].  
Among  200  asthmatic children  enrolled  in  an  asthma  program,  log  salivary  cotinine  level was 
independently associated with externalizing (p = 0.04), headstrong (p = 0.04) and antisocial behavior Int. J. Environ. Res. Public Health 2011, 8                 
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(p  =  0.04)  subscales  of  a  28-item  behavior  problem  index  [130].  Among  220  asthmatic  children 
enrolled in an asthma trial, child behavior problems (externalizing, i.e., hyperactivity and aggression, 
and internalizing, i.e., depression and behavior symptoms) increased with increased SHS exposure 
measured as serum cotinine, but the increase was significant only in boys [131].  
5.4. Fertility and Pregnancy  
For  issues  concerning  female  fertility  or  fecundability,  spontaneous  abortion,  preterm  delivery, 
congenital malformations, cognitive and behavioral development of the infant, height and growth, 
childhood  cancers,  leukemias,  and  lymphomas,  the  evidence  was  considered  inadequate  or  only 
suggestive of a causal relationship with exposure to SHS in the 2006 Surgeon General’s Report [2], but 
only a minority of studies relied on cotinine measures, and the latter with discordant results. 
In  Sweden,  a  population-based  case-control  study  was  conducted  between  1996  and  1998 
comparing exposure to SHS between 463 women with spontaneous abortion and 864 pregnant women 
as controls. The Adj OR of spontaneous abortion among SHS-exposed women (0.1–15 ng/mL plasma 
cotinine)  was  1.67  and  that  of  the  active  smokers  2.11  in  comparison  with  unexposed  
non-smokers [132]. 
Among 441 non-smoking pregnant women, the OR of discontinuation of any breastfeeding after the 
infant's first 6 months was 2.42 in women whose blood cotinine level was above the 75th percentile of 
cotinine distribution (>0.15 ng/mL) compared with mothers who had lower cotinine levels, with the 
corresponding OR of discontinuation of full breastfeeding at 1.71 [133]. 
Among numerous women whose mid-trimester cotinine levels were ≤10 ng/mL (non-smokers), the 
OR of fetal death and preterm delivery were 3.4 and 1.8, respectively, in the highest cotinine quintile 
(0.236–10 ng/mL) compared with the lowest quintile (<0.026 ng/mL) [134].  
The risk of preterm delivery (<37 weeks) was higher in a group of non-smoking women whose hair 
nicotine after delivery was >4.00 µ g/g (Adj OR 6.12) in comparison with those with the lowest hair 
nicotine concentration (<0.75 µ g/g) [135]. 
5.5. Sudden Infant Death Syndrome 
In the 2006 Report of the Surgeon General, the evidence was considered sufficient to confer a 
causal relationship between postnatal exposure to SHS and sudden infant death syndrome [2].  
5.6. Cancers 
In an European case-control study in non-smokers (190 controls and 149 cases, mostly all types of 
cancers), 4 ABP-Hb adducts, markers of carcinogenicity measured 7 years before the disease (median), 
were somewhat higher in cases than in controls [136]. In a large nested case-control study within the 
European prospective investigation into cancer and nutrition (EPIC), in which smoking status was 
supported by cotinine measurements, daily exposure to SHS for many hours during childhood was 
associated with lung cancer in adulthood (HR 3.63; 95% CI 1.19–11.11) [137].  
In addition to these papers, studies showing elevated levels of PPAH-gluc in the air of venues where 
smoking was allowed [9] or NNAL or NNAL-gluc, benzene and 1–3 butadiene in body fluids of  Int. J. Environ. Res. Public Health 2011, 8                 
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non-smokers [34,36,63,70,78,104], all markers of carcinogenicity, support the biological plausibility of 
the influence of SHS on the development of cancers, earlier demonstrated in epidemiological studies. 
5.7. Mental Health 
In a representative sample of 5,560 biologically validated (saliva cotinine < 15 µ g/L) non-smoking 
adults without a history of mental illness drawn from the 1998 and 2003 Scottish Health Surveys, 
higher saliva cotinine levels (>0.70 µ g/L) were associated with higher odds of psychological distress 
(OR 1.49; 95% CI 1.13–1.97) in comparison with participants with cotinine levels below the limit of 
detection (≤0.05 µ g/L). In the prospective analysis, the risk of psychiatric hospital admission  was 
related to high SHS exposures (multivariable adjusted HR 2.84; 95% CI 1.07–7.59) [138].  
The  trend  of  cognitive  impairment  (assessed  by  the  lowest  10%  of  scores  in  a  battery  of 
neuropsychological tests) in a cross-sectional analysis of a national population based survey of 4,809 
validated  non-smokers  in  England,  was  positively  related  with  increasing  concentrations  of  saliva 
cotinine (p for trend 0.02) after adjustment for other risk factors for cognitive impairment. The pattern 
of association was the same for never smokers and former smokers [139].  
5.8. Genotoxicity of SHS 
The issue of the genotoxicity of SHS was addressed in a recent review of human studies. Biomarker 
studies  carried  out  among  SHS-exposed  non-smoking  adults  show  the  presence  of  metabolites  of 
carcinogens  in  urine,  of  DNA  and/or  protein  adducts  in  peripheral  blood  or  other  non-malignant 
tissues, and the presence of micronuclei in bone marrow or peripheral blood. There is thus abundant 
evidence of the genotoxicity of SHS [140].  
6. Limitations 
The following limitations can be identified in the mentioned studies: 
(1)  The biological differentiation between active non daily smokers and passive smokers 
remains  critical,  due  to  overlapping  levels  of  biomarkers,  and  particularly  short-term 
biomarkers. The ―validated‖ definition of smokers, sometimes based on different cutoff 
levels of plasma cotinine, is a limitation for the validity of comparisons. 
(2)  Some of the studies can be biased through the use of ―convenience samples‖ instead of 
random  representative  sampling.  Participants  in  convenience  samples  may  be  more 
conscious of the SHS problems and more prone to implement the regulations [92,105]. 
The statistical power in some studies was limited [100]. 
(3)  The results of some studies were weakened by the low level of participation and/or by 
attrition during the process of inclusion or during follow-up [85,88,100,101]. 
(4)  The  multiple  sources  of  SHS  (also  outside  the  workplace  and  home)  are  sometimes 
unrecognized and can have a confounding effect that can impair the exact quantification 
of differences  in  markers between different areas  or  periods  [69].  The  prevalence  of 
active smoking can also influence the evolution of SHS exposure [90]. Nicotine and 
cotinine biomarkers can also be influenced by Nicotine Replacement Therapy. Int. J. Environ. Res. Public Health 2011, 8                 
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(5)  The level of compliance with the regulations is not always physically controlled and can 
play  a  role  on  the  quantified  values  observed  in  pre-and  post-ban  studies  or  in 
contemporaneous comparisons between different sites. 
7. Conclusions  
Earlier and principally recent SHS publications on air and biomarkers objectively: 
(1)  can  validate  the  smoking  status  obtained  via  self-report  (active  daily  smoker  versus  
non-smoker)  [1-3],  measure  the  percentages  of  inexact  self-reporting  in  different 
circumstances and show the possibility of understatement of  SHS exposures in some  
self-reports [84] (e.g., pregnancy) [77].  
(2)  confirm  the  toxin  intake  difference  between  non-smokers  not  exposed  (<0.05  ng/mL 
serum cotinine) and non-smokers exposed to SHS (<3 ng/mL serum cotinine) and thus 
the biological plausibility of the earlier epidemiological observations, a essential element 
for a causal link between SHS and disease [16]; the cut-off between passive and active 
smokers sometimes shifts towards larger values in periods or environments with higher 
SHS levels [15,105].  
(3)  quantify the level of exposure to air smoke toxicants through air markers and their intake 
through biomarkers in various locations and conditions and show its increase with the 
duration of exposure. Both are very different in various areas and both are the foundation 
for regulations and bans [42,45,104].  
(4)  show the possibility of “third hand smoke” due to sorption and desorption of nicotine 
from indoor surfaces, etc., while a limited contribution to SHS can result from retention 
of smoke in the lungs and its expiration after the last puffs [54] and also from infiltration 
from neighboring units [55] or from outdoor air [92]. 
(5)  show  the  deficiencies  of  mechanical  measures  in  controlling  SHS  (e.g.,  ventilation,  
non-physically separated areas for smokers and non-smokers) [10,44,46,83].  
(6)  objectify the control of SHS obtained by the implementation of total bans of smoking in 
public places, and the resulting reduction in prevalence of exposure in many Western 
countries [9,10,58,83,84,86,88,95,97,98,103,107,108], without a corresponding increase 
in SHS exposure outside the workplace [109].  
(7)  show  in  some  countries  the  good  level  of  implementation  of  the  bans 
[87,88,90,100,106,108],  which  was  unexpectedly  satisfactory,  even  in  some 
Mediterranean countries [93], but as the implementation sometimes decreases with time, 
also the necessity of its persistent control.  
(8)  demonstrate that partial bans reduce SHS exposure much less than total bans and that 
stringent  legislation  is  needed  (e.g.,  bans  of  smoking  rooms,  of  smoking  in  terraces 
outside cafes or restaurants whether covered or not, in airports, in discotheques, etc.) 
[41,43,64,68,92,99,105,110]. 
(9)  show that in the private domain (home), currently the main location of exposure to SHS, 
even if it is decreasing [72] (but not everywhere [109]), individual voluntary measures of 
protection are needed and complete control is obtained only with a total non-smoking Int. J. Environ. Res. Public Health 2011, 8                 
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policy at home or, but with lower efficacy, by allowing smoking exclusively outside  
the  home,  in  order  to  protect  children,  who  are  particularly  sensitive  to  SHS  
[53-55,75,79,111]. In cars, levels of nicotine and PM2.5 are high and not fully controlled 
by ventilation. They remain elevated even in secondhand cars sold by former smoking 
owners [47-50]. 
(10) demonstrate some health effects of SHS. All cause- and cardiovascular deaths are linked 
to  cotinine  levels  [113,114].  The  prognosis  of  coronary  heart  disease  is  negatively 
influenced by the levels of cotinine due to SHS exposure [115], evolving together with 
the levels of fibrinogen, homocystein and CRP (all correlated with the coronary risk) 
[113,118]. The increases in those markers of cardiovascular risk are much larger than the 
increase  in  cotinine.  This  can  explain  why  the  difference  in  coronary  risk  between 
passive  and  active  smokers  is  much  lower  than  what  could  be  expected  from  their 
differences in toxin intake [117]. SHS exposure is thus an important avoidable cause of 
cardiovascular disease. 
Negative short-term effects of experimental exposure to SHS [119] and of chronic SHS exposure 
[120] on respiratory functions are observed, but the minimal positive influence of a smoking ban on 
spirometric values is controversial, while a decrease in cough and phlegm is more evident [91,105,121] 
at least in non-smokers [85]. In established COPD, the severity of symptoms is increased by SHS 
exposure [122-124].  
Spontaneous abortions are more frequent among SHS-exposed non-smoking pregnant women than 
among unexposed non-smokers [132]. The prevalence of fetal death and preterm delivery are linked 
with biomarkers of exposure [134,135]. The early discontinuation of breastfeeding is more frequent 
when blood cotinine levels are in the range of SHS exposure [133]. The link between sudden infant 
death syndrome and exposure to SHS was already demonstrated by earlier studies [2]. 
There is limited biologically validated evidence of the influence of SHS on cancer prevalence [136], 
due  to  the  long  delay  between  exposure  and  disease,  but  the  observed  increase  in  biomarkers  of 
carcinogenicity [34,36,63,70,78,104] demonstrate the biological plausibility of a link between SHS 
and cancers, previously observed in epidemiological studies. 
Higher odds of psychological distress [138] and of cognitive impairment [139] are also associated 
with  increased  cotinine  levels.  Genotoxicity  of  SHS  is  shown  by  the  presence  of  carcinogen 
metabolites and of DNA adducts in blood and other tissues and by the presence of micronuclei in bone 
marrow or peripheral blood of non-smokers exposed to SHS [140]. 
In spite of the above mentioned limitations, given the consistency of the recent results (as opposed 
to some contradictions in the earlier periods), there is overwhelming evidence of local variations in 
exposure to SHS, of reductions in exposure after recent smoking bans, and of the effects of SHS on 
health parameters. 
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